Pfizer announced results from its Phase 3 study of axitinib for the treatment of metastatic renal cell carcinoma (mRCC) in previously treated patients. This trial met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally manageable safety profile in this study.
Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3. VEGF receptors 1, 2 and 3 appear to have roles in tumor growth, vascular angiogenesis and metastatic progression of cancer (the spread of tumors).
For more information call (800) 438-1985 or visit www.pfizer.com.